|
April 24, 2007
Allon Therapeutics Confirms Oral Bioavailability of AL-309
VANCOUVER, April 24, 2007— Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, today released new data confirming that the Company’s product AL-309 has robust oral bioavailability in preclinical studies. This new data also shows that AL-309 enters the brain and that effective concentrations can be detected for extended periods of time. This information serves to confirm the potential of AL-309 as a highly novel central nervous system drug.
April 19, 2007
From The Lab Bench To The Bedside: Guiding Researchers Across The Valley of Death Green Light for the Centre for Drug Research and Development
Vancouver, BC - April 19, 2007- The Centre for Drug Research and Development, a unique hybrid organization that helps health researchers collaborate, refine their discoveries and develop them for commercial use, is the recipient of a $25 million funding grant from the Province of British Columbia. Premier Gordon Campbell made the announcement at the 2007 British Columbia Biotech Awards last night.
April 19, 2007
LifeSciences BC Rewards BC's Brightest Young Scientists of the sanofi-aventis Biotech Challenge at its 9th Annual BC Biotechnology Awards Ceremony
Vancouver, British Columbia, April 19, 2007 – LifeSciences British Columbia presented $10,000 to the winning teams of the sanofi-aventis Biotech Challenge at its annual BC Biotech Biotechnology Awards Ceremony on Thursday, April 18, 2007.
April 17, 2007
OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting
VANCOUVER, April 17, 2007- OncoGenex Technologies Inc. announced today data from a Phase II clinical trial of OGX-011 in combination with docetaxel in patients with metastatic breast cancer (MBC). Data was presented by the National Cancer Institute of Canada - Clinical Trials Group at the American Association for Cancer Research 2007 Annual Meeting in Los Angeles, Calif.
April 17, 2007
Inex Pharmaceuticals Provides Progress Update on Alnylam Collaboration
VANCOUVER, BC, April 17, 2007 – Inex Pharmaceuticals Corporation ("INEX"; TSX: IEX) reported that one of its collaboration partners, Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), announced today that it will advance a systemically delivered RNA interference (RNAi) therapeutic, ALN-VSP01, for the treatment of liver cancer and potentially other solid tumors. The announcement was made at the American Association for Cancer Research (AACR) Annual Meeting being held in Los Angeles, California. The complete details of Alnylam’s announcement can be accessed from Alnylam’s website at www.anlylam.com.
April 16, 2007
California Superior Court Grants Preliminary Injunction Prohibiting Sirna From Using Protiva Technology
Vancouver, BC, April 16th, 2007- Protiva Biotherapeutics Inc. today reported that the California Superior Court has granted Protiva a preliminary injunction prohibiting Sirna Therapeutics Inc. from using, disclosing, transferring, licensing, selling or otherwise encumbering Protiva's trade secrets and know how, except as permitted in the target areas defined in the original Strategic Alliance Agreement (SAA) between the two companies.
April 10, 2007
BC Innovation Council Announces New Chief Executive Officer
Vancouver, BC, April 10, 2007- Hector MacKay-Dunn, QC, Chair, is pleased to announce that Matthew Watson has joined BC Innovation Council as Chief Executive Officer.
April 9, 2007
Inflazyme receives Helicon’s Statement regarding Preliminary Results of IPL455,903 in Phase 2a Memory Study
VANCOUVER, B.C., CANADA, April 9, 2007 – Inflazyme Pharmaceuticals Ltd. (TSX:IZP) today announced that it has received a statement from Helicon Therapeutics of New York regarding the outcome of the proof of concept Phase 2a study with IPL455,903 (HT-0712) in Age Associated Memory Impairment (AAMI).
April 3, 2007
MSFHR Program Heralds a New Way of Doing Business in Health Research
VANCOUVER- April 3, 2007– The Michael Smith Foundation for Health Research (MSFHR) announced today the successful applicants for funding from an innovative new program designed to pave the way for sharing research resources, information and expertise across the province’s health research institutions.
March 28, 2007
Forbes Medi-Tech announces Financial Results for the Year ended December 31, 2006
Vancouver, Canada – Forbes Medi-Tech Inc. (TSX:FMI; NASDAQ:FMTI) today announced its financial results for the year ended December 31, 2006 versus the year ended December 31, 2005. All amounts are in Canadian dollars unless otherwise noted. A conference call to discuss the financial statements will be held tomorrow, March 29, 2007 at 1:30pmPT /4:30pmET.
March 28, 2007
Protox Initiates Phase I Study of PRX302 for Benign Prostatic Hyperplasia
Vancouver, British Columbia, March 28, 2007 – ProtoxTM Therapeutics Inc. (TSX-V:PRX) announced today that it has initiated a Phase 1 clinical study of PRX302 for the treatment of benign prostatic hyperplasia (BPH, commonly known as enlarged prostate) at two Canadian sites.
March 28, 2007
Cardiome Reports 2006 Results
Vancouver, Canada, March 28, 2007 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today reported financial results for the fourth quarter and year ended December 31, 2006. Amounts, unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles (Canadian GAAP). At close of business on December 31, 2006, the exchange rate was CAD$1.00=US$0.8581.
March 27, 2007
Allon receives approval to begin a Phase II clinical trial for Schizophrenia
VANCOUVER, March 27, 2007 — Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, announced today that its IND (Investigational New Drug) application with the Unites States Food and Drug Administration (FDA), filed on February 20th 2007, is now active and the Company may begin human clinical trials evaluating the Company’s product AL-108 as a treatment for schizophrenia-related cognitive impairment. Allon was selected by the United States National Institute of Mental Health-funded project TURNS (Treatment Units for Research of Neurocognition in Schizophrenia) for a Phase II clinical trial.
March 27, 2007
Cardiome Announces Appointment of Chairman
Vancouver, Canada, March 27, 2007 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that current board member and Chief Executive Officer Bob Rieder has been elected as Chairman of the Company’s Board of Directors.
March 27, 2007
Cardiome To Release 2006 Results
Vancouver, Canada, March 27, 2007 -- Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that it will hold a teleconference call and webcast at 10:00am EST (7:00am PST) on Wednesday, March 28, 2007 to discuss year-end and fourth-quarter 2006 financial results.
March 26, 2007
LifeSciences BC Announces Recipients of the 2007 British Columbia Biotechnology Awards
Vancouver, British Columbia, March 26, 2007 – LifeSciences British Columbia today announced the recipients of the 2007 BC Biotechnology Awards.
March 26, 2007
Inimex Product Candidate is First Immune Defense Regulator to Cure Infections Without Causing Harmful Inflammation
VANCOUVER, British Columbia, March 26, 2007 – Inimex Pharmaceuticals Inc.’s product candidate IDR-1 is the first immune system trigger to cure infections without causing harmful inflammation, according to a paper published in the April 2007 issue of Nature Biotechnology.
March 20, 2007
Inex Pharmaceuticals Conference Call Advisory 2006 Year End Operating Results
VANCOUVER, BC – Inex Pharmaceuticals Corporation ("INEX"; TSX:IEX) announced today that it will hold a conference call and webcast on Wednesday March 21, 2007 at 9:00 am PST (12:00 noon EST) to discuss 2006 year end operating results and to provide an update on developments at the Company
March 20, 2007
Protox Announces Publication in Journal of the National Cancer Institute Supporting PRX302 as Treatment for Prostatic Diseases
Vancouver, British Columbia, March 20, 2007 – ProtoxTM Therapeutics Inc. (TSX-V:PRX) today announced that two peer-reviewed publications will feature Protox’s PRX 302. The Journal of the National Cancer Institute (“JNCI”) has published the work conducted by Dr. Sam Denmeade and his team at Johns Hopkins University in collaboration with Protox scientists. The paper describes the Company’s compound, PRX302, which is a prostate specific antigen (PSA) activated pro-drug being developed for the treatment of prostate cancer and BPH.
March 15, 2007
Pacgen Completes Patient Recruitment for Phase I/II Trial of Novel Anti-Fungal Drug
Vancouver, BC, Canada (March 15, 2007) – Pacgen Biopharmaceuticals Corporation (“Pacgen”) (TSX-V: PGA) announced today that it has completed the recruitment of patients in its Phase I/II study of PAC-113, a novel anti-fungal drug, in immunocompromised patients. The Company is on track to report proof of efficacy results from this study early in the second quarter of 2007.
March 15, 2007
Allon to present data at Alzheimer’s-Parkinson’s conference
VANCOUVER, March 15, 2007 — Allon Therapeutics Inc. (TSX: NPC), The Neuro Protection CompanyTM, today announced that Professor Illana Gozes, the Company’s Chief Scientific Officer, has been invited to speak to the 8th International Conference on Alzheimer’s and Parkinson’s Diseases in Salzburg, Austria March 18, 2007. More than 1,800 Alzheimer’s and Parkinson’s physicians and researchers from around the world will be attending the conference.
March 15, 2007
Zymeworks announces the addition of Mr. Neil Klompas CA to its Management Team
VANCOUVER, Canada, March 15 - Zymeworks Inc. announced today that Mr. Neil Klompas, CA has joined the company in the newly created position of Director, Finance and Operations. Mr. Klompas will be responsible for overseeing Zymeworks’ financial operations and contributing to corporate development.
March 14, 2007
NSERC Officially Opens New Pacific Regional Office in Vancouver
Vancouver, B.C., March 12, 2007 – The Honourable Maxime Bernier, Minister of Industry and Suzanne Fortier, President of the Natural Sciences and Engineering Research Council of Canada (NSERC) today announced the opening of a new NSERC regional office. Based in Vancouver, NSERC-Pacific will serve British Columbia and the Yukon.
March 13, 2007
Pacgen Appoints Robert DuFresne as President & CEO
Vancouver, BC, Canada, March 13, 2007 – Pacgen Biopharmaceuticals Corporation (“Pacgen”) (TSX-V: PGA) is pleased to announce the appointment of Robert 'Duffy' DuFresne as President and Chief Executive Officer. Mr. DuFresne replaces Dr. David Cheng who held the position since he co-founded the company in 2004. Dr. Cheng will continue to lead scientific affairs at Pacgen as Chief Scientific Officer and also as a Director. Mr. DuFresne will also be joining the Board as a Director.
March 12, 2007
Cardiome Board Chairman Retires
Vancouver, Canada, March 12, 2007 - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced the retirement of the Chairman of the Company's board of directors, Dr. Mark C. Rogers, effective today. Dr. Rogers had served as Board Chairman for approximately five years, since the merger of Cardiome with Paralex, Inc. in March 2002. Dr. Rogers also has resigned as a member of the Cardiome board.
March 7, 2007
Allon product AL-108 successful in Phase Ib clinical trial
VANCOUVER, March 7, 2007 – Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, announced today that the results of the completed Phase Ib clinical trial of their product AL-108 met all of its objectives. The trial confirmed that AL-108 is safe and well tolerated in 32 healthy elderly subjects after seven days of dosing.
March 5, 2007
EaglePicher Medical Power Releases World’s Smallest Implantable Medical Battery New Line of Micro Devices Are Now a Possibility
Vancouver, BC, Canada, 5 March 2007 – EaglePicher Medical Power today announced the successful qualification of the industry's smallest implantable-grade medical battery. The battery’s size and shape (cylindrical, 0.260” long x 0.090” diameter) enables a device so small that it can be deployed via a minimally-invasive catheter procedure rather than traditional implantation surgery. The device is presently undergoing clinical trials in Europe.
March 2, 2007
StemCell Technologies signs worldwide distribution agreement for ALDECOUNT with Aldagen
Vancouver, BC – March 2, 2007 – StemCell Technologies, Inc., a Vancouver-based life sciences company, announced today that it has signed a worldwide distribution agreement with Aldagen, Inc., a Durham, NC-based regenerative medicine company, whereby StemCell will distribute Aldagen’s ALDECOUNT® product. StemCell Technologies is also the worldwide distributor for Aldagen’s ALDEFLUOR® product.
March 2, 2007
Pacgen Reports Third Quarter Financial and Operating Results
Vancouver, BC, Canada (March 1, 2007) – Pacgen Biopharmaceuticals Corporation (“Pacgen”) (TSX-V: PGA) today reported financial results for the third quarter ended December 31, 2006. Amounts unless specified otherwise, are expressed in Canadian dollars and in accordance with Canadian Generally Accepted Accounting Principles.
March 1, 2007
Protox Outlines Milestones for 2007
Vancouver, British Columbia, March 1, 2007 – ProtoxTM Therapeutics Inc. (TSX-V:PRX) announced today the company’s key milestones for the coming year that will help position the company as a leader in targeted therapeutics for cancer and other proliferative diseases. They include the completion of a Phase I study in prostate cancer, the initiation of a Phase I study in benign prostatic hyperplasia and the initiation of a Phase IIb study in brain cancer. |
